Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons

Journal of Pineal Research

Volumn 60, Issue 1, 2016, Pages 95-108

  Benleulmi Chaachoua, Abla ^a,b   Chen, Lina ^c   Sokolina, Kate ^d   Wong, Victoria ^d   Jurisica, Igor ^e   Emerit, Michel Boris ^b,f   Darmon, Michèle ^b,f   Espin, Almudena ^a,b   Stagljar, Igor ^d   Tafelmeyer, Petra ^g   Zamponi, Gerald W ^c   Delagrange, Philippe ^h   Maurice, Pascal ^a,b,i,j   Jockers, Ralf ^a,b  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^g Hybrigenics SA   (France)

^h INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

ⁱ CNRS   (France)

^j UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

more..

Author keywords

G protein coupled receptor; melatonin; melatonin receptor; synapse

Indexed keywords

MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL; CACNA1B PROTEIN, HUMAN; CALCIUM CHANNEL N TYPE; NERVE PROTEIN;

ARTICLE; BRAIN CORTEX; CELL FRACTIONATION; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN CELL; HYPOTHALAMUS; IMMUNOFLUORESCENCE MICROSCOPY; NEUROTRANSMISSION; PRESYNAPTIC NERVE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; BRAIN; GENETICS; HEK293 CELL LINE; METABOLISM; NERVE ENDING;

BRAIN; CALCIUM CHANNELS, N-TYPE; HEK293 CELLS; HUMANS; NERVE TISSUE PROTEINS; PRESYNAPTIC TERMINALS; RECEPTOR, MELATONIN, MT1;

EID: 84954536679     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12294     Document Type: Article

References (79)

1. Reiter RJ, Tan DX, Kim SJ, et al., Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 2014; 219: 1873-1887.
2. Dubocovich ML, Delagrange P, Krause DN, et al., International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-380.
3. Tosini G, Owino S, Guillaume JL, et al., Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. BioEssays 2014; 36: 778-787.
4. Jockers R, Maurice P, Boutin JA, et al., Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 2008; 154: 1182-1195.
5. Zhang HM, Zhang Y,. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
6. Bonnefond A, Clement N, Fawcett K, et al., Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44: 297-301.
7. Hardeland R, Cardinali DP, Srinivasan V, et al., Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011; 93: 350-384.
8. Yi C, Pan X, Yan H, et al., Effects of melatonin in age-related macular degeneration. Ann N Y Acad Sci 2005; 1057: 384-392.
9. Wu YH, Ursinus J, Zhou JN, et al., Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord 2013; 148: 357-367.
10. Etain B, Dumaine A, Bellivier F, et al., Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21: 4030-4037.
11. Melke J, Goubran Botros H, Chaste P, et al., Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008; 13: 90-98.
12. Wu YH, Zhou JN, van Heerikhuize J, et al., Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2007; 28: 1239-1247.
13. Escribano BM, Colin-Gonzalez AL, Santamaria A, et al., The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. CNS Neurol Disord Drug Targets 2014; 13: 1096-1119.
14. Zisapel N,. Development of a melatonin-based formulation for the treatment of insomnia in the elderly. Drug Develop Res 2000; 50: 226-234.
15. Uchiyama M, Hamamura M, Kuwano T, et al., Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011; 12: 119-126.
16. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al., Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-642.
17. Liu C, Weaver DR, Jin X, et al., Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
18. Zisapel N, Egozi Y, Laudon M,. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res 1982; 246: 161-163.
19. Dubocovich ML,. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782-784.
20. Millan MJ, Gobert A, Lejeune F, et al., The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
21. Chenu F, El Mansari M, Blier P,. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 2013; 38: 275-284.
22. Wang LM, Suthana NA, Chaudhury D, et al., Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci 2005; 22: 2231-2237.
23. Larson J, Jessen RE, Uz T, et al., Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 2006; 393: 23-26.
24. Rawashdeh O, de Borsetti NH, Roman G, et al., Melatonin suppresses nighttime memory formation in zebrafish. Science 2007; 318: 1144-1146.
25. Ramirez-Rodriguez G, Klempin F, Babu H, et al., Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 2009; 34: 2180-2191.
26. Hutchinson AJ, Hudson RL, Dubocovich ML,. Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice. J Pineal Res 2012; 53: 399-409.
27. Uz T, Akhisaroglu M, Ahmed R, et al., The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice. Neuropsychopharmacology 2003; 28: 2117-2123.
28. Comai S, Ochoa-Sanchez R, Gobbi G,. Sleep-wake characterization of double MT(1)/MT(2) receptor knockout mice and comparison with MT(1) and MT(2) receptor knockout mice. Behav Brain Res 2013; 243: 231-238.
29. Schiller ED, Champney TH, Reiter CK, et al., Melatonin inhibition of nicotine-stimulated dopamine release in PC12 cells. Brain Res 2003; 966: 95-102.
30. Bockaert J, Perroy J, Becamel C, et al., GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies. Annu Rev Pharmacol Toxicol 2010; 50: 89-109.
31. Maurice P, Guillaume JL, Benleulmi-Chaachoua A, et al., GPCR-interacting proteins, major players of GPCR function. Adv Pharmacol 2011; 62: 349-380.
32. Gavarini S, Becamel C, Chanrion B, et al., Molecular and functional characterization of proteins interacting with the C-terminal domains of 5-HT2 receptors: emergence of 5-HT2 "receptosomes". Biol Cell 2004; 96: 373-381.
33. Meffre J, Chaumont-Dubel S, Mannoury LA, et al., 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Mol Med 2012; 4: 1043-1056.
34. Ramos C, Chardonnet S, Marchand CH, et al., Native presynaptic metabotropic glutamate receptor 4 (mGluR4) interacts with exocytosis proteins in rat cerebellum. J Biol Chem 2012; 287: 20176-20186.
35. Ayoub MA, Couturier C, Lucas-Meunier E, et al., Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002; 277: 21522-21528.
36. Maurice P, Daulat AM, Broussard C, et al., A generic approach for the purification of signaling complexes that specifically interact with the carboxy-terminal domain of G protein-coupled receptors. Mol Cell Proteomics 2008; 7: 1556-1569.
37. Guillaume JL, Daulat AM, Maurice P, et al., The PDZ protein mupp1 promotes Gi coupling and signaling of the Mt1 melatonin receptor. J Biol Chem 2008; 283: 16762-16771.
38. Fromont-Racine M, Rain JC, Legrain P,. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet 1997; 16: 277-282.
39. Formstecher E, Aresta S, Collura V, et al., Protein interaction mapping: a Drosophila case study. Genome Res 2005; 15: 376-384.
40. Rain JC, Selig L, de Reuse H, et al., The protein-protein interaction map of Helicobacter pylori. Nature 2001; 409: 211-215.
41. Wojcik J, Boneca IG, Legrain P,. Prediction, assessment and validation of protein interaction maps in bacteria. J Mol Biol 2002; 323: 763-770.
42. Snider J, Kittanakom S, Damjanovic D, et al., Detecting interactions with membrane proteins using a membrane two-hybrid assay in yeast. Nat Protoc 2010; 5: 1281-1293.
43. Gietz RD, Woods RA,. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006; 313: 107-120.
44. Daulat AM, Maurice P, Froment C, et al., Purification and identification of G protein-coupled receptor protein complexes under native conditions. Mol Cell Proteomics 2007; 6: 835-844.
45. Huttner WB, Schiebler W, Greengard P, et al., Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 1983; 96: 1374-1388.
46. Beedle AM, McRory JE, Poirot O, et al., Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 2004; 7: 118-125.
47. Kisilevsky AE, Mulligan SJ, Altier C, et al., D1 receptors physically interact with N-type calcium channels to regulate channel distribution and dendritic calcium entry. Neuron 2008; 58: 557-570.
48. Carrel D, Masson J, Al Awabdh S, et al., Targeting of the 5-HT1A serotonin receptor to neuronal dendrites is mediated by Yif1B. J Neurosci 2008; 28: 8063-8073.
49. Brown KR, Jurisica I,. Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol 2007; 8: R95.
50. Kotlyar M, Pastrello C, Pivetta F, et al., In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods 2015; 12: 79-84.
51. Brown KR, Otasek D, Ali M, et al., NAViGaTOR: network analysis, visualization and graphing Toronto. Bioinformatics 2009; 25: 3327-3329.
52. Daulat AM, Maurice P, Jockers R,. Recent methodological advances in the discovery of GPCR-associated protein complexes. Trends Pharmacol Sci 2009; 30: 72-78.
53. Hosaka M, Hammer RE, Sudhof TC,. A phospho-switch controls the dynamic association of synapsins with synaptic vesicles. Neuron 1999; 24: 377-387.
54. Deery MJ, Maywood ES, Chesham JE, et al., Proteomic analysis reveals the role of synaptic vesicle cycling in sustaining the suprachiasmatic circadian clock. Curr Biol 2009; 19: 2031-2036.
55. Tallent MK, Varghis N, Skorobogatko Y, et al., In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J Biol Chem 2009; 284: 174-181.
56. Carrel D, Simon A, Emerit MB, et al., Axonal targeting of the 5-HT1B serotonin receptor relies on structure-specific constitutive activation. Traffic 2011; 12: 1501-1520.
57. Evans RM, You H, Hameed S, et al., Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J Biol Chem 2010; 285: 1032-1040.
58. Gerdin MJ, Masana MI, Ren D, et al., Short-term exposure to melatonin differentially affects the functional sensitivity and trafficking of the hMT(1) and hMT(2) melatonin receptors. J Pharmacol Exp Ther 2003; 304: 931-939.
59. Levoye A, Dam J, Ayoub MA, et al., The orphan GPR50 receptor specifically inhibits MT(1) melatonin receptor function through heterodimerization. EMBO J 2006; 25: 3012-3023.
60. Bondi CD, McKeon RM, Bennett JM, et al., MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation. J Pineal Res 2008; 44: 288-298.
61. Barry J, Gu Y, Jukkola P, et al., Ankyrin-g directly binds to Kinesin-1 to transport voltage-gated na(+) channels into axons. Dev Cell 2014; 28: 117-131.
62. Leterrier C, Laine J, Darmon M, et al., Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci 2006; 26: 3141-3153.
63. Roka F, Brydon L, Waldhoer M, et al., Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity. Mol Pharmacol 1999; 56: 1014-1024.
64. Devavry S, Legros C, Brasseur C, et al., Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. J Pineal Res 2012; 53: 29-37.
65. Deak F, Shin OH, Tang J, et al., Rabphilin regulates SNARE-dependent re-priming of synaptic vesicles for fusion. EMBO J 2006; 25: 2856-2866.
66. Pan PY, Tian JH, Sheng ZH,. Snapin facilitates the synchronization of synaptic vesicle fusion. Neuron 2009; 61: 412-424.
67. Holt M, Varoqueaux F, Wiederhold K, et al., Identification of SNAP-47, a novel Qbc-SNARE with ubiquitous expression. J Biol Chem 2006; 281: 17076-17083.
68. Zamponi GW, Currie KP,. Regulation of Ca(V)2 calcium channels by G protein coupled receptors. Biochim Biophys Acta 2013; 1828: 1629-1643.
69. Kisilevsky AE, Zamponi GW,. D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels. Channels (Austin) 2008; 2: 269-277.
70. Khanna R, Zougman A, Stanley EF,. A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners. J Biochem Mol Biol 2007; 40: 302-314.
71. Muller CS, Haupt A, Bildl W, et al., Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain. Proc Natl Acad Sci USA 2010; 107: 14950-14957.
72. Cardinali DP, Nagle CA, Freire F, et al., Effects of melatonin on neurotransmitter uptake and release by synaptosome-rich homogenates of the rat hypothalamus. Neuroendocrinology 1975; 18: 72-85.
73. Zisapel N, Laudon M,. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: inhibition by melatonin. Biochem Biophys Res Commun 1982; 104: 1610-1616.
74. Zisapel N, Laudon M,. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Res 1983; 272: 378-381.
75. Escames G, Macias M, Leon J, et al., Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. J Neuroendocrinol 2001; 13: 459-466.
76. Jiang Z, Nelson C, Allen C,. Melatonin activates an outward current and inhibits lh in rat suprachiasmatic nucleus neurons. Brain Res 1995; 687: 125-132.
77. van den Top M, Buijs RM, Ruijter JM, et al., Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience 2001; 107: 99-108.
78. Huan CL, Zhou MO, Wu MM, et al., Activation of melatonin receptor increases a delayed rectifier K+ current in rat cerebellar granule cells. Brain Res 2001; 917: 182-190.
79. Orchard S, Ammari M, Aranda B, et al., The MIntAct project-IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res 2014; 42: D358-D363.